GENELINK ADDS KEY MEMBER TO ITS MEDICAL BOARD 
August 15, 2002

Margate, NJ, August 15, 2002-GeneLink BioSciences, Inc. (OTCBB:GNLK), a biosciences company that has developed genetic assessments for customizing nutritional and skin care regimens, announced today that it has entered into an agreement with Robert J. Schwarzberg, M.D., F.A.C.C. to serve as a medical consultant to the Company. He will assist and coordinate all medical issues relating to GeneLink's genetic assessment of cardiovascular health as GeneLink rolls out its genetic profiling technologies program. 

Dr. Schwarzberg is a board certified cardiologist and fellow of the American College of Cardiology. He received his medical degree from Wayne State University and B.A. from Columbia University. Dr. Schwarzberg brings extensive experience in telemedicine and disease management to this position. He has been a leader in the telemedicine industry since 1989. As Chairman and Medical Director of Cardiolife, a national cardiac monitoring company, Dr. Schwarzberg was instrumental in its business and technology development from a startup to $18M in revenue with substantial intellectual property including a patent he authored on a hybrid smart event recorder. In 1996, he became Chief Medical Officer of Ralin Medical and its subsidiaries - Cardiac Solutions (now CorSolutions) and LifeWatch. Dr. Schwarzberg is currently CMO of LifeWatch, the largest arrhythmia management company in the United States. 

GeneLink BioSciences, Inc., a pioneer DNA banking and hereditary genetic information service, has developed a proprietary method for genetic assessments (patents pending) and is beginning to license these breakthrough nutragenetic and dermagenetic profiles to companies that market or manufacture products for the $100 billion plus skin care, nutritional supplement, and health care industries. For more information about GeneLink, visit its website at www.genelink.info. 

"I am very pleased to be involved with GeneLink", says Dr. Schwarzberg. "The Company has created an exciting new category of genomic assessments that can help people make more appropriate health related choices. GeneLink's technologies may forever change the way consumers choose nutritional supplements and skin care products." 

"We are very proud to welcome such a dignified member of the medical community to our team. Dr. Schwarzberg's experience and expertise will play an important role in our plans to license our genetic profiling technologies to companies both nationally and internationally", says John R. DePhillipo, Chairman of GeneLink BioSciences, Inc. 

Forward-Looking Statements: This press release contains certain forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement. GNLK disclaims any intention or obligation to revise any forward-looking statements whether as a result of new information, future developments or otherwise.

SOURCE: GeneLink BioSciences, Inc.